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Abstract
We retrospectively studied the single and combined diag-
nostic value of carcinoembryonic antigen (CEA), cytoke-
ratin fragment 19 (CYFRA 21-1), neuron specific enolase
(NSE) and pro-gastrin-releasing peptide (ProGRP), which
were routinely analysed in patients with lung tumours of
unknown origin at the time of admission to hospital.
Inclusion criteria were the determination of CEA (AxSYM/
Abbott), CYFRA 21-1 (ElecSys/Roche) and NSE (Kryptor/
Brahms). We examined 1747 patients, where 1325
suffered from lung cancer (LC; small cell lung cancer,
SCLC: ns194; non-small cell lung cancer, NSCLC:
ns1015; others: ns116), 318 from benign lung diseases
and 104 from lung metastases due to another primary
malignancy. As ProGRP (ELISA ALSI/IBL) became avail-
able only recently, there are less data points of this
marker. In total, 99.8% of LC patients released at least
one of the four biomarkers (defined as values exceeding
the median of healthy controls), and for the discrimination
between benign disease (BD) and malignant lung disease
each marker reached 100% tumour specificity at high
levels (CEA: 20 ng/mL; CYFRA 21–1: 40 ng/mL; NSE:
45 ng/mL; ProGRP: 250 pg/mL). At a specificity of
)99%, ProGRP reached the highest diagnostic efficacy
for SCLC with 57% true positive results, CEA had the
highest capacity (17%) to detect malignant lung tumours
in general and adenocarcinomas of the lung with 29%.
CYFRA 21-1 was dominant for squamous cell carcino-
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mas (12%). Combining the four markers leads with the
prerequisite of high specificity ()99%) to 50% true pos-
itives for malignant lung tumours, 44% for NSCLC, 36%
for squamous cell carcinomas, 53% for adenocarcino-
mas, and 78% for SCLC, respectively. In cases of lung
tumours of unknown origin, the combined use of CEA,
CYFRA 21-1, NSE and ProGRP is useful for the differ-
entiation between benign and primary or secondary
malignant disease and suggests the assignment to his-
tological subtypes.
Keywords: carcinoembryonic antigen (CEA); cytokeratin
fragment 19 (CYFRA 21-1); logistic regression; lung can-
cer; multivariate analysis; neuron specific enolase (NSE);
pro-gastrin-releasing peptide (ProGRP).
Zusammenfassung
Im Rahmen einer retrospektiven Analyse wurde die dia-
gnostische Wertigkeit von CEA, CYFRA 21-1, NSE und
ProGRP untersucht – einzeln und in Kombination – die
im Rahmen der stationa¨ren Aufnahme zur Abkla¨rung
eines Lungentumors routinema¨ssig angefordert wurden.
Einschlusskriterium war das Vorhandensein von CEA
(AxSYM/Abbott), CYFRA 21-1 (ElecSys/Roche) und NSE
(Kryptor/Brahms) bei jedem Patienten. Wir untersuchten
insgesamt die Proben von 1747 Patientlnnen, darunter
1325 Patientlnnen mit einem Lungenkarzinom (sLC,
kleinzelliges Lungenkarzinomssmall cell lung cancer
SCLC: ns194, nicht kleinzelliges Lungenkarzinomsnon
small cell lung cancer NSCLC: ns1015, andere Subfor-
men: ns116), sowie 318 Proben von Patientlnnen mit
benignen Lungenerkrankungen und Proben von 104
Patientlnnen mit Lungenmetastasen aufgrund eines
anderen Prima¨rtumors. Da ProGRP (ELISA ALSI/IBL) erst
seit einigen Jahren fu¨r Routinemessungen verfu¨gbar ist,
ist die Anzahl der ProGRP messungen geringer vergli-
chen mit den 3 anderen Biomarkern.
99.8% der LC PatientInnen setzten mindestens einen
der 4 Biomarker gesteigert frei ()Median gesunder Kon-
trollen), bei hohen Konzentrationen erreichte jeder der 4
Marker zur Unterscheidung zwischen benigner (BD) und
maligner Lungenerkrankung eine 100%ige Tumorspezi-
fita¨t (CEA: 20 ng/mL; CYFRA 21-1: 40 ng/mL; NSE:
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45 ng/mL; ProGRP: 250 pg/mL). Bei einer Spezifita¨t
)99% erreichte ProGRP mit 57% richtig positiven
Testergebnissen die ho¨chste diagnostische Effizienz fu¨r
SCLC, CEA hatte mit 17% die ho¨chste Fa¨higkeit zur
Entdeckung eines malignen Lungenrundherdes im allge-
meinen sowie mit 29% zur Entdeckung von Adenokar-
zinomen der Lunge. CYFRA 21-1 dominierte in der Ent-
deckung von Plattenepithelkarzinomen (12%). Basierend
auf der Forderung einer 99%igen Spezifita¨t fu¨hrte die
Kombination aller 4 Marker zur Entdeckung von 50% der
malignen Lungenrundherde, von 44% fu¨r das NSCLC,
36% fu¨r Plattenepithelkarzinome, 53% fu¨r Adenokarzi-
nome und 78% fu¨r kleinzellige Karzinome.
Zusammenfassend kann festgestellt werden, dass im
Falle von unklaren Lungentumoren die kombiniertte
Bestimmung von CEA, CYFRA 21-1, NSE und ProGRP
sowohl fu¨r die Diffeenzierung zwischen benignen und
malignen Lungenrundherden hilfreich ist, als auch die
Zuordnung zu histologischen Subtypen von malignen
Lungentumoren ermo¨glicht.
Schlu¨sselwo¨rter: Cytokeratin 19-Fragment (CYFRA 21-
1); Karzinoembryonales Antigen (CEA); Logistiche
Regression; Lungenkarzinom; Multivariate Analyse; Neu-
ronspezifische Enolase (NSE); ProGastrin Releasing Pep-
tid (ProGRP).
Introduction
Lung cancer is the most frequent cancer in the world,
both in terms of incidence (1.2 million new cases or
12.3% of the world total) and mortality (1.1 million deaths
or 17.8% of the total). For males, it is by far the most
common cancer worldwide (incidence rate 34.9 per
100,000). In females, incidence rates are lower (11.1 per
100,000). Trends in lung cancer incidence and mortality
are related to the smoking epidemic in different countries.
In men, several populations have passed the peak of
tobacco consumption, and incidence and mortality
decrease slowly in the USA and several European coun-
tries. In contrast, most western countries show a rising
trend in incidence and mortality in women w1–3x.
Histopathologically, lung cancer is divided into two
types: non-small cell and small cell lung cancer (NSCLC
and SCLC). The former consists of several subtypes, pre-
dominantly adenocarcinoma, squamous cell carcinoma
and large cell carcinoma. SCLC is a more aggressive car-
cinoma with neuroendocrine capacities and accounts for
15% to 25% of lung cancer patients. Many lung cancers
constitute histologically mixed tumour types consisting
of non-small cell and small cell components w4–6x.
Patients with lung cancer, particularly in the early stag-
es, often do not exhibit specific signs and symptoms.
Dyspnoea, cough, thoracic pain are considered non-spe-
cific early signs, haemoptysis may already indicate
advanced stages of lung cancer. Relapsing infectious
diseases of the respiratory system in combination with a
smoking history might be an indication for further exam-
ination. The diagnostic work-up for lung cancer includes
medical history and physical examination, clinical labo-
ratory testing, chest radiography, computed tomography
or magnetic resonance imaging of the chest, abdomen
and the brain, bronchoscopy, biopsy, bone scan, pre-
operative pulmonary function studies, and eventually
positron emission tomography, bone marrow biopsy and
thoracentesis w5, 6x.
Histological differentiation and lung cancer staging is
mandatory for therapeutic stratification. For patients with
NSCLC, particularly for those with early stages (I–IIIA),
surgery is the mainstay of treatment. The additional appli-
cation of adjuvant radio- or chemotherapy provides only
minimal benefit in certain subgroups of patients which
are difficult to define by current techniques. The use of
neoadjuvant systemic therapy to provoke tumour shrink-
age and early eradication of systemic micrometastases
is still a matter of debate w4, 5x. Five-year survival rates
depend strongly on tumour stage with 60% to 70% for
stage I, 40% to 50% for stage II, and 15% to 30% for
stage IIIA w5x. Currently, virtually no patient with non-
resectable non-small lung cancer in advanced stage (IIIB
and IV) will be cured. Median survival for stage IV patients
has been stable for years at 8–10 months. Although
response rates for chemo- and radiotherapy are low, sev-
eral studies have demonstrated moderate beneficial
effects concerning survival, time to disease progression,
and quality of life, as compared with best supported care
(reviewed in w4x). Combined radio-chemotherapy is sug-
gested particularly for patients with stage IIIB disease w4,
7x. Patients with stage IV disease are mostly treated by
chemotherapeutic regimens, except for those with loca-
lised single metastases who may be eligible for surgical
resection w4, 5, 7x.
Small cell lung cancer is characterised by a rapid dou-
bling time and its propensity for early metastases. In con-
trast to NSCLC, staging is only related to the extent of
disease that alters prognosis and treatment decisions. In
clinical practice, only two stages of SCLC are distin-
guished: limited stage disease (LD) with the tumour con-
fined to one hemithorax only versus extensive stage
disease (ED) with metastases in the opposite chest or at
distant sites. In total, 20% to 25% of patients will have
limited disease, which can be treated with curative inten-
tion. However, the 5-year survival rates are still low (15%
to 25%, compared to extensive disease with -5%). In
these patients, a multimodal approach of chemo- and
radiotherapy is recommended followed by prophylactic
cranial irradiation to prevent cerebral metastases.
Lung cancer belongs to a set of solid tumours releas-
ing oncological biomarkers, including carcinoembryonic
antigen (CEA) w8x, cytokeratin fragment 19 (CYFRA 21-1)
w9–14x, neuron specific enolase (NSE) w15x and pro-gas-
trin-releasing factor (ProGRP) w16–20x at an early stage
of disease into blood. Selected biomarkers, notably NSE
and ProGRP, have the diagnostic advantage to be
released only by one of the various histological subtypes
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of lung cancer, namely SCLC. Therefore, they might be
valuable for the differential diagnosis particularly when a
biopsy cannot be performed for topographic or clinical
reasons. The clinical value of the information provided by
tumour markers in these cases is crucial, because the
therapeutic approach strongly depends on the classifi-
cation as SCLC versus NSCLC.
Furthermore, the decrease of tumour markers after
surgery may indicate the completeness of the removal of
tumour tissue or the presence of micrometastatic resi-
dues. Intensity of the follow-up schedule can be sup-
ported by tumour marker kinetics. Moreover, the pre- and
post-therapeutic concentrations provide additional prog-
nostic information to the clinical staging that will be help-
ful for further therapeutic stratification, particularly if
histologically mixed tumour types are present or several
adjuvant therapies are available.
The aim of the present investigation was to answer the
following questions: How efficient is the combined use
of the biomarkers CEA, CYFRA 21-1, NSE and ProGRP
for the discrimination between benign and malignant lung
diseases? Are these markers able to discriminate
between primary lung cancer and lung metastases due
to another primary malignancy? Do these markers sup-
port histological classification?
Patients and methods
Study design and patients
This retrospective study includes 1747 patients who were
referred to the Department of Thoracic Surgery during the
years 1986–2003, either to clarify the diagnosis of lung
tumours of unknown origin or to operate on already
known malignant lung tumours.
Inclusion criteria were pre-therapeutic values of CEA,
CYFRA 21-1 and NSE. ProGRP became available only
3 years ago resulting in less data points.
Of the 1747 patients, 1325 suffered from primary lung
cancer, 318 had benign lung diseases and 104 patients
had lung metastases due to another primary malignancy.
The characteristics of the patients are provided in Table 1.
Patients with NSCLC were classified according to UICC
(Union Internationale Contre le Cancer) staging, patients
suffering from SCLC were grouped according to limited
versus extensive disease.
Gastrointestinal cancer was the most frequent primary
malignancy (ns37) in the lung metastases group
(ns104), followed by urogenital cancer (ns25), breast
cancer (ns16), lymphoma/sarcoma (ns4), cancer of
endocrine origin (ns5), cancer of the ear, nose and throat
(ns5), and of unknown origin (ns12).
The group of 318 patients with benign lung diseases
included patients with acute infections (tuberculosis,
pneumonia, pleural empyema, pleuritis and bronchitis),
acute lung disease (pneumothorax, pleural effusion,
haemoptysis and atelectasis), chronic lung disease
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(sarcoidosis, aspergilloma, bronchogenic cyst, lung cyst,
hamartoma, chronic pneumonia, pleural fibrosis, COPD
(chronic obstructive pulmonary disease), chronic bron-
chitis, bronchial asthma, pulmonary emphysema, bron-
chiectasis, pneumoconiosis, interstitial lung disease,
pulmonary fibrosis) and benign lung tumours.
Assays
All tumour markers were assessed using commercial kits
in the Institute of Clinical Chemistry of the University
Hospital of Großhadern, Munich. For CEA, the AxSYM
test system employing the principle of microparticle
enzyme immunoassay (MEIA) from Abbott Diagnostics
(Chicago, Illinois, USA) was used. There were methodical
changes during the time course of data collection for the
tumour markers CYFRA 21-1 and NSE. CYFRA 21-1 was
initially measured by the enzyme immunoassay (EIA) on
the ES 600 system of Boehringer Mannheim (Mannheim,
Germany) and later by the Elecsys EIA by Roche Diag-
nostics (Mannhein, Germany). Samples of 114 patients
were analysed for CYFRA 21-1 using both tests. For the
purpose of this specific study, we performed a regression
analysis (Passing-Bablok algorithm), including CYFRA
21-1 values-15 ng/mL. This range of values was select-
ed, as low to moderate concentrations of oncological
biomarkers are of special importance for diagnostic pur-
poses. CYFRA 21-1 values of the ES 600 test were con-
verted by the equation: CYFRA 21-1 (Elecsys)sCYFRA
21-1 (ES 600)–0.3, if the CYFRA 21-1 (ES 600) value was
)0.4 ng/mL to avoid negative concentrations.
For NSE analyses, three different methods were used:
Pharmacia Diagnostics Sweden (RIA) (Uppsala, Sweden),
Roche Diagnostics on the Cobas Core (EIA), and KRYP-
TOR TRACE by Brahms Diagnostica (Berlin, Germany).
For 183 patients with parallel determinations using the
tests by Pharmacia and Roche and NSE values -20
ng/mL, the Passing-Bablok regression equation was:
NSE (Cobas)s1.52=NSE (Pharmacia)–1.826. Further-
more, we calculated the Passing-Bablok regression for
189 patients measured with Cobas Core and KRYPTOR
TRACE principle. The result was NSE (KRYP-
TOR)s0.769=NSE (Cobas)q1.008. It should be noted
that the former calculations would not apply for routine
purposes.
For ProGRP, the ELISA principle by ALSI (Saitama,
Japan) (IBL, Hamburg, Germany) was used.
Statistical analysis
Tumour marker values are tabulated as median, quartiles
and range for the different groups of benign lung dis-
eases, metastases due to another primary malignancy,
and lung cancer as well as its subdivision into SCLC and
NSCLC. In addition, box plots (median, 5th and 95th per-
centile, extreme values as dots) for the four markers and
the major diagnostic groups of benign lung diseases,
lung metastases and primary lung cancer were per-
formed using a logarithmic scale.
To analyse associations between tumour marker val-
ues and T, N and M stage for the NSCLC group and
between tumour marker values and the stage of limited
disease and extensive disease for the SCLC group,
respectively, a trend test on ranks of values was per-
formed. Correlations between different tumour markers
were calculated using the Spearman rank coefficient.
To compare the serum tumour markers CEA, CYFRA
21-1, NSE and ProGRP for their ability to discriminate
between benign and malignant lung diseases, specificity
and sensitivity was calculated using the receiver oper-
ating characteristic (ROC) in addition to the area under
the curve (AUC), which was calculated as the Wilcoxon
rank sum test statistic and a test of the null hypothesis
that the AUC is 50% versus the alternative that it
exceeds 50%. Sensitivities for the single markers and
their combined use were calculated at a specificity of
)99% for benign lung diseases.
For a logistic regression model, biomarkers were
included as continuous variables on a natural logarithmic
scale.
The coefficients of the logistic regression model allow
for the calculation of a score. Scores presented in this
study are calculated using leave-one-out validation,
meaning that for each patient those coefficients were
used which are based on a model which was calculated
without this patient.
Results
Tumour marker values
Figure 1 demonstrates box plots for the four tumour
markers in benign diseases, lung metastases and pri-
mary lung cancer. As compared to benign lung diseases,
values of all four tumour markers were significantly higher
for patients with primary lung cancer (ps0.0000 for CEA,
CYFRA21-1 and NSE; ps0.004 for ProGRP), and CEA
and CYFRA21-1 also for patients with lung metastases
due to another primary malignancy (CEA: ps0.001;
CYFRA 21-1: ps0.0001). This difference was less pro-
nounced for NSE (ps0.04) and did not reach significance
for ProGRP (ps0.7). Differences between patients with
primary lung cancers and patients with lung metastases
were only significant for CEA (ps0.0003) and CYFRA 21-
1 (ps0.005).
Tumour marker values (median and 95% percentiles)
for histological subgroups of lung cancer patients are
provided in Table 2. As compared to patients with
NSCLC, ProGRP values were markedly elevated in
patients with SCLC, and to a lower extent also NSE
levels. No difference was found for CEA, whereas
CYFRA21-1 values were slightly lower in patients with
SCLC.
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Figure 1 Distribution of CEA, CYFRA 21-1, NSE and ProGRP (medians, quartiles, 5th and 95th percentiles, highest values in dots)
in benign lung diseases (ns318), lung metastases (ns104) and primary lung cancer (ns1325).
In the NSCLC group, the highest CEA values were
reached in adenocarcinomas, followed by large cell car-
cinomas, whereas in squamous cell carcinomas levels
were significantly lower. In contrast, CYFRA 21-1 values
were highest in squamous cell carcinomas, followed by
large cell carcinomas and lowest in adenocarcinomas.
The highest values of NSE were found for large cell car-
cinomas. No differences between histological subtypes
of NSCLC were obtained for ProGRP.
We classified patients with NSCLC according to UICC
staging and patients with SCLC into extensive and lim-
ited disease (Table 3). Significantly increasedmarker con-
centrations were observed with more advanced tumour
stages in patients with NSCLC for the tumour markers
CEA (p-0.0001), CYFRA 21-1 (p-0.0001) and NSE
(ps0.001). Patients suffering from SCLC with extensive
disease showed significantly higher CEA (p-0.05),
CYFRA 21-1 (ps0.0002) and NSE (ps0.0000) concen-
trations compared to limited disease. With regard to
ProGRP, there was no significant correlation with tumour
stage for SCLC or for NSCLC.
Each marker reached 100% tumour specificity at high
levels. For CEA, the value is 20 ng/mL, for CYFRA 21-1
it is 40 ng/mL, for NSE it is 45 ng/mL, and for ProGRP
it is 250 pg/mL, respectively. Considering 100% specific-
ity, CEA reached the best diagnostic sensitivity for malig-
nancy (lung metastases and primary lung cancer) with
12.5%, followed by ProGRP with 9%, NSE with 6% and
CYFRA 21-1 with only 2%. Furthermore, we looked at
99% specificity of each tumour marker for benign lung
diseases and calculated at this value the sensitivity of the
markers for the differential diagnosis benign lung dis-
eases, lung metastases and lung cancer, and histological
subtypes. Table 3 demonstrates that all four markers are
able to discriminate between benign and malignant lung
diseases, whereas CEA is the most efficient with 17%
compared to 0.3% in the benign lung diseases group.
Except for ProGRP, which reached a sensitivity of 13%
in the lung cancer group in comparison to 0% in the lung
metastases group, no marker could differentiate between
lung cancer and lung metastases at the high cut-off level.
Regarding the NSCLC and SCLC groups, the markers
NSE (40% SCLC versus 3% NSCLC) and ProGRP (57%
SCLC versus 2% NSCLC) are able to discriminate
between these two groups. In the NSCLC subgroups, the
highest sensitivity of CEA (29%) is reached in adenocar-
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cinoma, whereas CYFRA 21-1 (12%) is dominant in the
squamous cell carcinoma group. The markers NSE and
ProGRP are not able to differentiate the NSCLC
subgroups.
We also examined the sensitivities for the same groups
if at least one tumour marker reached 99% specificity.
For this observation, the sensitivity for SCLC is the high-
est with 78%, whereas the other groups reached a
sensitivity of approximately 50%.
Multivariate discrimination between benign and
malignant lung diseases
To quantify the diagnostic capacity of the different
tumour markers, we used a logistic regression model
including age and all four tumour markers without pre-
destinated cut-off values (Table 5). Only CEA, CYFRA 1-
1 and NSE, as well as age provided significant diagnostic
information. The additional diagnostic information of
ProGRP was non-significant, thus it was excluded from
the final analysis.
Regarding the influence of age on the probability of
malignancy, a quadratic term was required. The highest
probability for malignancy was between the ages of 55
to 70 years.
From the coefficients of the model, the following score
can be calculated:
Score (malignancy)s0.2676=Age–0.00208=Age2q
0.9932=log (CEA)q1.3774=log (CYFRA 21-1)q
0.7453=log (NSE)–11.3808. We calculated this score,
however, using leave-one-out validated coefficients.
Figure 2 shows ROC curves of the score in comparison
to single tumour markers. Of these, CYFRA 21-1 reached
the best AUC (0.79), followed by CEA (0.72); whereas,
the two markers NSE (0.59) and ProGRP (0.57) had less
diagnostic relevance. The AUC of the score (0.839) of the
combined use of the three tumour markers CYFRA
21-1, CEA and NSE, as well as the age is superior to the
AUCs of the single markers.
As mentioned above, values of ProGRP were not avail-
able for all patients and therefore the ROC curve of
ProGRP is not directly comparable to the ROC curves of
the other tumour markers. Using only patients with all
four markers available (benign lung diseases: ns171,
malignant lung diseases: ns632), the results are com-
parable with the results using the whole sample (CYFRA
21-1: AUCs0.76, CEA: AUCs0.73, NSE: AUCs0.65,
ProGRP: AUCs0.57).
Furthermore, the 1669 patients of the multivariate anal-
ysis were subdivided into five equal groups and the
amount of benign lung diseases and the amount of
malignant lung diseases were counted for each sub-
group. The proportions of benign lung diseases and of
malignant lung diseases are illustrated in Figure 3. It is
evident that the probability of benign lung disease
declines continuously, whereas the probability of malig-
nant lung disease increases with higher score levels.
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Table 5 Logistic regression for the discrimination between benign lung disease and malignant lung disease (Lnsnatural logarithm).
Variable Coefficient Standard p Odds ratio 95% Confidence
error limits
Age 0.2676 0.0491 -0.0001 1.307 1.187–1.439
Age2 –0.00208 0.000416 -0.0001 0.998 0.997–0.999
Ln CEA 0.9932 0.1320 -0.0001 2.700 2.084–3.497
Ln CYFRA 21-1 1.3774 0.1610 -0.0001 3.964 2.892–5.436
Ln NSE 0.7453 0.1802 -0.0001 2.107 1.480–3.000
Constant –11.3808 1.4946 -0.0001
Figure 2 ROC curves and AUC of CEA, CYFRA 21-1, NSE and ProGRP and the established score for benign lung diseases and
malignant lung diseases.
Figure 3 Leave-one-out validated score divided in quintiles:
percentage of patients with benign and malignant lung diseases.
Discrimination between primary lung cancer and
lung metastases due to another primary malignancy
The second question focused on the differentiation
between primary lung cancer and metastases due to
another primary malignancy. It is evident from Figure 1
that the two markers NSE and ProGRP differentiate best
between these two groups. For NSE, the highest value
in the group of lung metastases was 43 ng/mL, for
ProGRP it was 55.4 pg/mL, this value is even lower than
the highest value in the group of benign lung diseases
(ProGRP: 244 pg/mL). CEA (highest value for metasta-
ses: 2861 ng/mL), though being statistically significant,
is not able to discriminate between primary lung cancer
and lung metastases due to another primary malignancy.
For CYFRA 21-1 (highest value for metastases: 30.4
ng/mL), the situation is improved but remains non-signifi-
cant.
Support of histological classification NSCLC versus
SCLC
For this purpose, the AUC and the 100% specificity were
calculated and illustrated by ROC. The superiority of the
two markers NSE and ProGRP was evident. For NSE, an
AUC of 0.802 was calculated, for ProGRP the AUC was
only slightly lower (0.759). For the calculation of the ROC
curve for CYFRA 21-1, we used the reciprocal value,
because a high value of CYFRA 21-1 is significant for
NSCLC. The AUC of the two tumour markers CEA (0.494)
and CYFRA 21-1 (0.568) was negligibly small. Regarding
the 100% specificity of the single markers, only ProGRP
and NSE reached 100% specificity. The best result was
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Figure 4 ROC curves and AUC of CEA, CYFRA 21-1, NSE and ProGRP and the established score for SCLC and NSCLC.
Table 6 Logistic regression for the discrimination between SCLC and NSCLC (Lnsnatural logarithm).
Variable Coefficient Standard p Odds ratio 95% Confidence
error limits
Ln CYFRA 21-1 –0.8117 0.2041 -0.0001 0.444 0.298–0.663
Ln NSE 1.5727 0.2456 -0.0001 4.820 2.978–7.800
Ln ProGRP 0.6975 0.1217 -0.0001 2.009 1.582–2.550
Constant –7.3405 0.6874 -0.0001
reached by ProGRP with 12.8%, whereas NSE reached
6.2%.
A further regression model was used to analyse the
histological differentiation power into NSCLC or SCLC of
the combination of the four tumour markers. In this
model, the three tumour markers CYFRA 21-1, NSE and
ProGRP provided significant differentiation between
NSCLC and SCLC and thus were included in the final
analysis (Table 6). The score was calculated as follows:
Scores–0.8117=log(CYFRA21-1)q1.5727=log(NSE)
q0.6975=log (ProGRP)–7.3405.
Figure 4 illustrates the calculated ROC curve for the
score compared with the ROC curves of the single mark-
ers. The AUC of the score reached with 0.836 the best
result compared to the single used markers. Even the
100% specificity reached with 22.9% higher values than
the single markers as reported in the univariate analysis.
Discussion
A number of biomarkers have been described to be of
potential diagnostic relevance for lung cancer. The bio-
markers most frequently investigated include CEA,
CYFRA 21-1 and NSE, but also squamous cell carcinoma
antigen (SCCA), cancer antigen 125 (CA 125) and tissue
polypeptide antigen (TPA). More recently a new biomark-
er was included in many investigations, namely ProGRP,
which has become of significant diagnostic relevance for
SCLC.
Based on the various histological lung cancer sub-
types, it is evident that in contrast to other solid tumours
a panel of biomarkers is needed to reach a satisfying high
sensitivity for NSCLC and SCLC patients. Therefore,
many investigations deal with different combinations of
biomarkers w20–31x.
This present investigation is based on the biomarkers
CEA, CYFRA 21-1, NSE and ProGRP following locally
issued guidelines (Tumorzentrum Mu¨nchen, http://
tumourzentrum-muenchen.de). These analyses are rou-
tinely performed in patients before primary surgery of
lung cancer or in patients with suspicious signs of lung
cancer. Here, we evaluated the additional diagnostic or
differential diagnostic capacity of lung cancer biomarkers
at the time of primary diagnosis.
Concerning the first clinical question if biomarkers are
able to give diagnostic aid in the differentiation between
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benign and malignant lung tumours, there is no trial
described in the literature which is based on a compa-
rable high number of patients and focused from the out-
set on a histological subtype of lung cancer or a special
stage of tumour disease. In addition, most investigations
are only based upon univariate procedures.
Our findings revealed that very high concentrations of
all four biomarkers are able to discriminate between
benign and malignant lung tumours, corresponding to
the clinical experience that from a certain level of these
oncological biomarkers CEA, CYFRA 21-1, NSE and
ProGRP the probability of a malignant solid tumour is
very high. The most sensitive marker is CEA with 17%
sensitivity, the combination of all four markers leads to a
clear improvement with 50% sensitivity.
Plebani et al. w31x studied seven tumour markers (NSE,
SCC, CEA, CYFRA 21-1, TPA (Tissue Polypeptide Anti-
gen), TPM (Tissue Polypeptide Monoclonal Antigen) and
TPS (Tissue Polypeptide Specific Antigen)) to evaluate
their diagnostic efficiency in SCLC and NSCLC. Com-
parable with our results, this study showed that all
tumour markers had significantly higher values in patients
with lung cancer compared with those who suffer from
benign lung diseases. ROC analysis revealed that the
highest diagnostic accuracies in distinguishing benign
from malignant lung diseases were achieved with TPM
(81%, sensitivity 79% and specificity 84%), CYFRA 21-1
(72%, sensitivity 64% and specificity 86%), CEA (78%,
sensitivity 89% and specificity 56%) and TPA (78%, sen-
sitivity 82% and specificity 71%). Our results revealed
comparable findings, although our aim was the very high
specificity of )99% in order to avoid false positive
results. As the former investigation was performed with-
out fixed specificities, it is impossible to compare results
in further detail.
We conclude from the data presented that the bio-
markers CEA, CYFRA 21-1, NSE and ProGRP each reach
100% tumour specificity at very high levels and that their
combined use is able to differentiate between benign and
malignant lung diseases with a 50% sensitivity.
The next clinical question examined if it is possible to
differentiate by using biomarkers between a primary lung
tumour or lung metastases from another primary malig-
nancy. As expected, CEA and CYFRA 21-1 are unable to
reach the high specificity as they are released by almost
all other solid tumours. However, the combination of
CYFRA 21-1 and ProGRP allows, with a sensitivity of
21.2% and a specificity of 100%, to differentiate between
primary lung cancer and lung metastases due to another
primary malignancy. The combination of NSE and
ProGRP reached a sensitivity of 17.6%, followed by the
single use of ProGRP with 15.9%. The superiority of NSE
and ProGRP to answer this question may be explained
by the fact that NSE and especially ProGRP are mostly
released by lung cancer, in contrast to CEA and CYFRA
21-1 being rather a marker for all malignancies. There-
fore, we conclude that high NSE or ProGRP values are
very suggestive of a primary lung cancer. This question
has, to the best of our knowledge, not yet been
addressed in the literature.
Having diagnosed a primary lung cancer it is impera-
tive to provide histological differentiation between SCLC
and NSCLC for its importance for prognostic and thera-
peutic reasons. Therefore, we studied the supportive
power of tumour markers with regard to histology.
Concerning the differentiation of SCLC patients from
NSCLC patients, high concentrations of CEA and CYFRA
21-1 could be observed predominantly within the group
of NSCLC patients. Especially for CYFRA 2-1, this finding
has been described previously by several investigators
w21, 24, 32–35x. In our investigation, a CYFRA 21-1-value
)100 ng/mL was only observed in patients suffering
from NSCLC.
However, the best discrimination between NSCLC and
SCLC could be achieved by using NSE and ProGRP, as
previously described w18, 29x.
In multivariate analysis, CYFRA 21-1, NSE and Pro-
GRP turned out to be significant factors for the differ-
entiation between SCLC and NSCLC patients. The
corresponding score leads to improvement of the AUC
from 0.802 for NSE as best single marker to 0.836 for
the combination.
In conclusion, we state that the multivariate use of the
biomarkers CEA, CYFRA 21-1, NSE and ProGRP leads
to an increase of the diagnostic capacity for the discrim-
ination between benign and malignant lung tumours, as
well as for the discrimination between NSCLC and SCLC.
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